Spero Therapeutics continues to accumulate assets through acquisitions. This morning, the Cambridge, MA-based startup announced a deal to grab rights to a group of experimental antibiotic compounds from Vertex Pharmaceuticals (NASDAQ:VRTX), among them a drug called VXc-486/VXc-100. Spero didn’t disclose the financial terms, just that it will make an upfront payment to Vertex and promise future milestones and royalties if the drugs progress.
The deal is the latest in a group of licensing agreements Spero has used to amass different ways of attacking troublesome drug-resistant bacteria, so-called “superbugs” that can resist common antibiotics. The startup, formed by Atlas Venture in 2014, has already grabbed rights to experimental drugs through pacts with Northern Antibiotics and Promiliad Biopharma. Check out this post for more on the thinking behind those deals, and Spero’s strategy.